Company news

Pfizer, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan

April 23, 2026

Pfizer Declares Second-Quarter 2026 Dividend

April 22, 2026

Drug Delivery Devices Market Insights, Competitive Landscape, and Forecast Report 2025-2032 - Growing Use of Biologics and Biosimilars, Technological Advancements, and Active Product Developments

April 22, 2026

Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026

April 21, 2026

U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

April 20, 2026

Frontier Medicines Appoints Veteran Drug Development Leader David R. Epstein to Board of Directors

April 13, 2026

Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders

April 9, 2026

Telix Strengthens Board with Additional Director Appointments

April 8, 2026

Global Ischemic Hepatitis Treatment Market Led by North America as Pfizer and Novartis Expand Therapies

April 6, 2026

Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts

March 24, 2026

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

March 23, 2026

Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

March 20, 2026

TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer

March 19, 2026

Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

March 17, 2026

Ngenla (somatrogon: Pfizer) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

March 13, 2026

Elrexfio (Pfizer: epcoritamab) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

March 10, 2026

Neumega (Pfizer, (Wyeth Pharmaceuticals)) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F

March 10, 2026

Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis

March 9, 2026

AI in Pharma Manufacturing Market Research 2026-2040: Pfizer, Moderna, Novartis, Merck, and Sanofi are Integrating AI Into Their Operations As the Sector Evolves Towards Pharma 4.0

March 3, 2026

Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors

March 2, 2026

PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

February 27, 2026

Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

February 26, 2026

ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing

February 25, 2026

U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

February 24, 2026

Sciwind Biosciences Partners with Pfizer China to Commercialize its Biased GLP-1 in China

February 24, 2026

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

February 23, 2026

Pfizer’s BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer

February 17, 2026

Pfizer Becomes Newest Partner Added to BaseLaunch's Biotech Venture Incubator

February 10, 2026

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea

February 9, 2026

FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need

February 6, 2026

Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans

February 5, 2026

Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance

February 3, 2026

Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial

February 3, 2026

Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

January 22, 2026

AI in Drug Discovery Market Research Report 2026-2040: NVIDIA, Insilico Medicine, Google DeepMind, Pfizer, and Roche Leveraging AI Platforms to Accelerate Development Timelines and Reduce R&D Costs

January 19, 2026

Pfizer’s BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer

January 10, 2026

Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor

January 9, 2026

Boltz and Pfizer Announce Strategic Collaboration to Develop and Deploy State-of-the-Art Biomolecular AI Foundation Models

January 8, 2026

Gordian Bio Announces Research Collaboration with Pfizer to Accelerate In Vivo Target Discovery in Obesity

January 8, 2026

Cartography Biosciences and Pfizer to Collaborate on the Discovery of Tumor-Selective Antigens

January 6, 2026

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

January 5, 2026

Flagship Pioneering and Repertoire® Immune Medicines Announce Agreement to Identify T Cell-Targeted Immune Medicines for Prostate Cancer Under Strategic Partnership with Pfizer

December 22, 2025

New York State's 2025 Emerging Technology Advisory Board Releases Final Report to Boost Biotech Innovation, Commercialization and Public Health Impact

December 19, 2025

Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts

December 18, 2025

PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

December 17, 2025

Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance

December 16, 2025

Pfizer Declares First-Quarter 2026 Dividend

December 12, 2025

TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer

December 10, 2025

Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma

December 9, 2025

HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors

December 6, 2025

← Newer news releases · Older news releases →

Calls

The 5 newest of 31 calls. Every call is listed under its year.

Decks

The 5 newest of 200 decks. Every deck is listed under its year.